Joshua Bauml

Lung Cancer Das Leader @Johnson & Johnson Innovative Medicine

Philadelphia, PA, US
MOBILE NUMBERS
+91 *********19

Signup · Get unlimited contacts

WORK HISTORY

Jul 2024 — Present

Lung Cancer Das Leader @Johnson & Johnson Innovative Medicine

View department →

Spring House, PA, US

As the Lung Cancer DAS leader, I am responsible for the end-to-end Lung Cancer Development at Johnson and Johnson Innovative Medicines including mature assets (Rybrevant and lazertinib) as well as identifying new assets in early development and/or partnerships.

EDUCATION

2004 — 2008

Icahn School of Medicine at Mount Sinai

Doctor of Medicine (M.D.), Philosophy and Drama

2000 — 2004

Tufts University

Bachelor's degree

SKILLS

OncologyLung CancerMedicineInternal MedicineCancerClinical ResearchPublic SpeakingMolecular BiologyMedical EducationEpidemiologyHealthcare Information TechnologyClinical TrialsHead and Neck CancerBoard Certified

ABOUT JOSHUA BAUML

Vice President, Lung/H&N Cancer Disease Area Stronghold (DAS) Leader

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

Joshua Bauml — Lung Cancer Das Leader at Johnson & Johnson Innovative Medicine in Philadelphia, PA, US | Unifers